Adenine

• 

  Subject Areas on Research

  • A colony color method identifies the vulnerability of mitochondria to oxidative damage. 
  • A strong effect of AT mutational bias on amino acid usage in Buchnera is mitigated at high-expression genes. 
  • Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. 
  • Activity of Galidesivir in a Hamster Model of SARS-CoV-2. 
  • Activity of psoralen-functionalized nanoscintillators against cancer cells upon X-ray excitation. 
  • Acute renal failure after initiation of tenofovir disoproxil fumarate. 
  • Adefovir dipivoxil in chronic hepatitis B: history and current uses. 
  • Adenine and adenosine are toxic to human lymphoblast mutants defective in purine salvage enzymes. 
  • Adenine auxotrophic mutants of Aspergillus oryzae: development of a novel transformation system with triple auxotrophic hosts. 
  • Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. 
  • An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral. 
  • Analysis of the mouse transcriptome for genes involved in the function of the nervous system. 
  • Antiretroviral medications: adverse effects on the kidney. 
  • Antiretroviral preexposure prophylaxis for HIV prevention. 
  • Atomic structures of excited state A-T Hoogsteen base pairs in duplex DNA by combining NMR relaxation dispersion, mutagenesis, and chemical shift calculations. 
  • Base stacking and molecular polarizability: effect of a methyl group in the 5-position of pyrimidines. 
  • C-C bond forming radical SAM enzymes involved in the construction of carbon skeletons of cofactors and natural products. 
  • Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. 
  • Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. 
  • Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments. 
  • Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. 
  • Complete Response of a Young Woman With MYD88WT Bing-Neel Syndrome on Ibrutinib Monotherapy Following a Single Cycle of B Hyper-CVAD/IT MTX. 
  • Concerning the mechanism of FSH action: rapid stimulation of testicular synthesis of nuclear RNA. 
  • Coordinate regulation of the proximal and distal steps of the pathway of purine synthesis de nono in WI-L2 human lymphoblasts. 
  • Crystal structure and sequence-dependent conformation of the A.G mispaired oligonucleotide d(CGCAAGCTGGCG). 
  • Crystal structures of adenine phosphoribosyltransferase from Leishmania donovani. 
  • Cytotoxic and metabolic effects of adenosine and adenine on human lymphoblasts. 
  • Design of tenofovir-UC781 combination microbicide vaginal gels. 
  • Determinants of Photolyase's DNA Repair Mechanism in Mesophiles and Extremophiles. 
  • Development of a novel quadruple auxotrophic host transformation system by argB gene disruption using adeA gene and exploiting adenine auxotrophy in Aspergillus oryzae. 
  • Differential specificities and simultaneous occupancy of human MutSalpha nucleotide binding sites. 
  • Distinct MutS DNA-binding modes that are differentially modulated by ATP binding and hydrolysis. 
  • Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies. 
  • Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMD. 
  • EcoRI methylase. Physical and catalytic properties of the homogeneous enzyme. 
  • Economic evaluation of ART in resource-limited countries. 
  • Effects of high levels of DNA adenine methylation on methyl-directed mismatch repair in Escherichia coli. 
  • Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. 
  • Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. 
  • Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. 
  • Efficient sporulation of yeast in media buffered near pH6. 
  • Escherichia coli mutY gene encodes an adenine glycosylase active on G-A mispairs. 
  • Escherichia coli mutY gene product is required for specific A-G----C.G mismatch correction. 
  • Expanding the diversity of DNA base modifications with N⁶-methyldeoxyadenosine. 
  • Extended storage of AS-1 and AS-3 leukoreduced red blood cells for 15 days after deglycerolization and resuspension in AS-3 using an automated closed system. 
  • Extent of equilibrium perturbation of the DNA helix upon enzymatic methylation of adenine residues. 
  • FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. 
  • Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients. 
  • Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. 
  • Flipping of the ribosomal A-site adenines provides a basis for tRNA selection. 
  • Gout and the regulation of purine biosynthesis. 
  • HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. 
  • Hepatitis B virus viral load and treatment decision. 
  • Hypoxanthine uptake in isolated rat renal cortical tubule fragments. 
  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. 
  • Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. 
  • Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. 
  • Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. 
  • Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. 
  • Ibrutinib: a new targeted therapy for hematologic cancers. 
  • Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. 
  • Insight into the CSA tensors of nucleobase carbons in RNA polynucleotides from solution measurements of residual CSA: towards new long-range orientational constraints. 
  • Insights into Watson-Crick/Hoogsteen breathing dynamics and damage repair from the solution structure and dynamic ensemble of DNA duplexes containing m1A. 
  • Kidney disease in patients with HIV infection and AIDS. 
  • Kinetic studies of hydrogen bonding. 1-Cyclohexyluracil and 9-ethyladenine. 
  • Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. 
  • Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. 
  • Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. 
  • Methyl-directed DNA mismatch repair in Escherichia coli. 
  • Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver. 
  • Mitochondrial DNA polymorphism A4917G is independently associated with age-related macular degeneration. 
  • Mitotic phosphorylation of eukaryotic initiation factor 4G1 (eIF4G1) at Ser1232 by Cdk1:cyclin B inhibits eIF4A helicase complex binding with RNA. 
  • Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. 
  • Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel. 
  • Newer treatments for HIV in children. 
  • Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. 
  • Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. 
  • Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. 
  • Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. 
  • Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. 
  • Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. 
  • Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy. 
  • Phase II study of amonafide in advanced pancreatic adenocarcinoma. 
  • Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. 
  • Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. 
  • Polyglutamine expansion inhibits respiration by increasing reactive oxygen species in isolated mitochondria. 
  • Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. 
  • Preexposure prophylaxis for HIV infection among African women. 
  • Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. 
  • Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. 
  • Purine reutilization and synthesis de novo in APRT deficient long-term lymphocyte lines. 
  • Purine reutilization and synthesis de novo in long-term human lymphocyte cell lines deficient in adenine phosphoribosyltransferase activity. 
  • Purine toxicity in human lymphoblasts. 
  • Recognition sequence of the dam methylase of Escherichia coli K12 and mode of cleavage of Dpn I endonuclease. 
  • Rejuvenation solution as an adjunct cold storage solution maintains physiological haemoglobin oxygen affinity during early-storage period of red blood cells. 
  • Removal of N-6-methyladenine by the nucleotide excision repair pathway triggers the repair of mismatches in yeast gap-repair intermediates. 
  • Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. 
  • Robust IR-based detection of stable and fractionally populated G-C+ and A-T Hoogsteen base pairs in duplex DNA. 
  • Role of transmethylation reactions in cellular motility and phagocytosis. 
  • Salmonella typhimurium SA host specificity system is based on deoxyribonucleic acid-adenine methylation. 
  • Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. 
  • Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. 
  • Site-specific methylases induce the SOS DNA repair response in Escherichia coli. 
  • Structure-based redesign of corepressor specificity of the Escherichia coli purine repressor by substitution of residue 190. 
  • Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. 
  • Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma. 
  • Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). 
  • Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. 
  • Tenofovir alafenamide for HIV infection: is less more? 
  • The C-terminal domain of the adenine-DNA glycosylase MutY confers specificity for 8-oxoguanine.adenine mispairs and may have evolved from MutT, an 8-oxo-dGTPase. 
  • The conserved dinucleotide AG of the 3' splice site may be recognized twice during in vitro splicing of mammalian mRNA precursors. 
  • The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry. 
  • The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. 
  • The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. 
  • Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. 
  • Transmethylation reactions are required for initial morphologic and biochemical responses of human monocytes to chemoattractants. 
  • Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. 
  • Unraveling the structural complexity in a single-stranded RNA tail: implications for efficient ligand binding in the prequeuosine riboswitch. 
  • Urine processing impacts uric acid level in HIV-infected adults: implications for diagnosing tenofovir-associated proximal tubulopathy. 
  • Urolithiasis under atazanavir boosted and tenofovir therapy: a case report. 
  • Vaginal deployment and tenofovir delivery by microbicide gels. 
  • Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity? 
  • m6A and YTHDF proteins contribute to the localization of select neuronal mRNAs. 
  • m6A-mediated translation regulation.